Your browser doesn't support javascript.
loading
Tumor-infiltrating Lymphocytes are Independent Favorable Prognostic Indicator in 17-year Disease-Free Survival in Lymph Node-Negative Triple-Negative Breast Cancer Patient.
Br J Med Med Res ; 2016; 15(8): 1-15
Artigo em Inglês | IMSEAR | ID: sea-183121
ABSTRACT

Aims:

To estimate the prognostic value of tumor-infiltrating lymphocytes, among other variables, in triple-negative breast cancer patients with a 17-year disease-free survival. Study

Design:

A retrospective study of 79 patients was conducted to investigate treatment, and clinical, microscopic and immunohistochemical tumor characteristics. Place and Duration of Study Pathology Division, National Cancer Institute (INCA), Rio de Janeiro, RJ, Brazil, between January 1992 and December 1996.

Methodology:

Histologically diagnosed 79 node-negative triple-negative breast cancer patients underwent partial or total mastectomy with axillary lymphadenectomy, with or without radiotherapy, chemotherapy and/or hormone therapy. Disease-free survival was estimate by the Kaplan-Meier method and log-rank test. Prognostic variables were obtained by Cox regression models.

Results:

The 17-year disease-free survival was 50.6%. Disease-free survival was worse in patients aged 51-82 years, who underwent neoadjuvant chemotherapy and had skin compromise, geographic necrosis, grade 3 tumors, had no tumor-infiltrating lymphocytes, had vascular/lymphatic invasion, CD44+/CD24-/low and elevated Ki-67. The risk of recurrence and/or metastasis, adjusted for the remaining variables of the final Cox model was 2.44 times higher for patients aged 51-82 years, 2.60 times higher for patients undergoing neoadjuvant chemotherapy, 3.97 times higher for grade 3 tumors and 0.34 times for patients with tumor-infiltrating lymphocytes.

Conclusion:

The risk of recurrence and/or metastasis, adjusted for the remaining variables of the model, was about 2.5 times higher for older patients undergoing neoadjuvant chemotherapy. In grade 3 tumor patients, the risk increased almost fourfold. Patients with tumor-infiltrating lymphocytes had a 66% lower risk, i.e, tumor-infiltrating lymphocytes were shown to be a protective factor.

Texto completo: DisponíveL Índice: IMSEAR (Sudeste Asiático) Tipo de estudo: Estudo observacional / Estudo prognóstico Idioma: Inglês Revista: Br J Med Med Res Ano de publicação: 2016 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: IMSEAR (Sudeste Asiático) Tipo de estudo: Estudo observacional / Estudo prognóstico Idioma: Inglês Revista: Br J Med Med Res Ano de publicação: 2016 Tipo de documento: Artigo